Rezolute, Inc. RZLT · Stock Open Rezolute, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Rezolute, Inc. Analysis (RZLT)
Is Rezolute, Inc. a good investment? Rezolute, Inc. (RZLT) is currently trading at 3.96 USD. Market analysts have a consensus price target of 9.80 USD. This suggests a potential upside from current levels.
Earnings Schedule: Rezolute, Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -0.47.
Investor FAQ
Does Rezolute, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Rezolute, Inc.?
Rezolute, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -0.75.
Company Profile
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
| Split Date | Split Ratio to 1 |
|---|---|
| May 1, 2014 | 0.17 |
| Oct. 13, 2020 | 1:50 |
Community Discussion